These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28803791)

  • 1. Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
    Minato A; Fujimoto N; Kubo T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1063-e1067. PubMed ID: 28803791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
    Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
    Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
    Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
    Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
    [No Abstract]   [Full Text] [Related]  

  • 5. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
    Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
    Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
    Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
    Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
    Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
    Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
    Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
    Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis.
    Mitra AP; Bartsch CC; Bartsch G; Miranda G; Skinner EC; Daneshmand S
    Urol Oncol; 2014 Feb; 32(2):117-27. PubMed ID: 23477878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.
    Thomas DE; Kaimakliotis HZ; Rice KR; Pereira JA; Johnston P; Moore ML; Reed A; Cregar DM; Franklin C; Loman RL; Koch MO; Bihrle R; Foster RS; Masterson TA; Gardner TA; Sundaram CP; Powell CR; Beck SDW; Grignon DJ; Cheng L; Albany C; Hahn NM
    Clin Genitourin Cancer; 2017 Aug; 15(4):479-486. PubMed ID: 28040424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
    Hinata N; Hussein AA; George S; Trump DL; Levine EG; Omar K; Dasgupta P; Khan MS; Hosseini A; Wiklund P; Guru KA
    BJU Int; 2017 Apr; 119(4):605-611. PubMed ID: 27743481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
    Drakaki A; Pantuck A; Mhatre SK; Dhillon PK; Davarpanah N; Degaonkar V; Surinach A; Chamie K; Grivas P
    Urol Oncol; 2021 Jan; 39(1):76.e15-76.e22. PubMed ID: 32778476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).
    Scosyrev E; Ely BW; Messing EM; Speights VO; Grossman HB; Wood DP; de Vere White RW; Vogelzang NJ; Trump DL; Natale RB; Tangen CM; Crawford ED; Thompson IM
    BJU Int; 2011 Sep; 108(5):693-9. PubMed ID: 21105991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
    Liew MS; Azad A; Tafreshi A; Eapen R; Bolton D; Davis ID; Sengupta S
    BJU Int; 2013 Nov; 112 Suppl 2():74-82. PubMed ID: 24127680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
    Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
    J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy.
    Zareba P; Patterson L; Pandya R; Margel D; Hotte SJ; Mukherjee SD; Elavathil L; Daya D; Shayegan B; Pinthus JH
    Urol Oncol; 2014 Oct; 32(7):975-80. PubMed ID: 25027682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of squamous histology in bladder cancer: a population-based study.
    Izard JP; Siemens DR; Mackillop WJ; Wei X; Leveridge MJ; Berman DM; Peng Y; Booth CM
    Urol Oncol; 2015 Oct; 33(10):425.e7-13. PubMed ID: 26199176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for bladder cancer.
    Sonpavde G; Lerner SP
    Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.